Siva Kaliyamoorthy^1,2, Varadharajaperumal Radhakrishnan¹, Mutharasu Arasu² and Jawahar Ramasamy¹*

¹Associate Professor, Department of Pathology, Aarupadai Veedu Medical College and Hospital, Vinayaka Mission’s Research Foundation (Deemed to be university), Kirumampakkam Puducherry, India
²Associate Professor, Department of Pathology, Sri Manakula Vinayagar Medical College and Hospital, Puducherrya

*Corresponding Author: Jawahar Ramasamy, Professor, Department of Pathology, Aarupadai Veedu Medical College and Hospital, Vinayaka Mission’s Research Foundation (Deemed to be university), Kirumampakkam Puducherry, India.

Received: November 01, 2021; Published: December 21, 2021

Abstract

Endometrial hyperplasia is defined as an abnormal proliferation of the endometrium with increased gland to stroma ratio and abnormalities in epithelial cells linked to prolonged exposure to estrogen stimulation. Endometrial curettings and hysterectomy specimens diagnosed with Endometrial Hyperplasia cases diagnosed with histopathologically were subjected to Immunohistochemical examination for Estrogen and Progesterone receptor status using DAKO monoclonal Estrogen Receptor (ER) and Progesterone Receptor (PR) antibody kit. A semiquantitative scoring system (H score system) has employed and a composite score of grade of intensity and percentage of stained cells. Most of the cases received and taken up for study belonged to the Reproductive age group of 18-46. The commonest clinical diagnosis of these cases was Dysfunctional uterine bleeding. Simple hyperplasia without atypia (SH) was found to be the commonest histopathological diagnosis in patients with Dysfunctional uterine bleeding. H scores of ER and PR in the glandular epithelial cells of these cases was showed PR scores being higher than ER in cases of SH. With the advent of newer hormonal therapies which can prove beneficial in avoiding surgical management, knowing the status of estrogen and progesterone receptors in the hyperplastic endometrium can prove a better therapeutic option compared to hysterectomy. Hormonal therapy using progestins can be tried before surgical management in patients with endometrial hyperplasia because the receptor status is favorable.

Keywords: Endometrial Hyperplasia; Estrogen Receptor; Progesterone Receptor; Dysfunctional Uterine Bleeding

References

1. Robbins S Kumar., et al. “pathologic basis of disease. 8^th”. Saunders Philadelphia, PA (2010).
2. Palter S and Olive D. “Reproductive physiology”. Williams and Wilkins, Baltimore (1996).
3. Wang C., et al. “Estrogen Receptor, Progesterone Receptor, and HER2 Receptor Markers in Endometrial Cancer”. Journal of Cancer7 (2020): 1693-1701.
4. Haines M., et al. “Haines and Taylor Obstetrical and Gynaecological Pathology”. Churchill Livingstone (2003).
5. Fedchenko N and Reifenrath J. “Different approaches for interpretation and reporting of immunohistochemistry analysis results in the bone tissue-a review”. Diagnostic Pathology1 (2014): 1-12.
6. Reed SD., et al. “Progestin therapy of complex endometrial hyperplasia with and without atypia”. Obstetrics and Gynecology3 (2009): 655.
7. Chakraborty S., et al. “Endometrial hormone receptors in women with dysfunctional uterine bleeding”. Archives of Gynecology and Obstetrics1 (2005): 17-22.
8. Gleeson N., et al. “Cyclical variation in endometrial oestrogen and progesterone receptors in women with normal menstruation and dysfunctional uterine bleeding”. European Journal of Obstetrics and Gynecology and Reproductive Biology3 (1993): 207-214.
9. Israel R., et al. “Mechanisms of normal and dysfunctional uterine bleeding”. Clinical Obstetrics and Gynecology2 (1970): 388-399.
10. Takreem A., et al. “Incidence of endometrial hyperplasia in 100 cases presenting with polymenorrhagia/menorrhagia in perimenupausal women”. Journal of Ayub Medical College Abbottabad2 (2009): 60-63.
11. Bergeron C., et al. “Immunocytochemical study of progesterone receptors in hyperplastic and neoplastic endometrial tissues”. Cancer Research21 (1988): 6132-6136.
12. Mylonas I., et al. “Immunohistochemical labelling of steroid receptors in normal and malignant human endometrium”. Acta Histochemica4 (2009): 350-360.
13. Soper JT., et al. “Estrogen and progesterone receptor content of endometrial carcinomas: comparison of total tissue versus cancer component analysis”. Gynecologic Oncology3 (1990): 363-368.
14. Mutch DG., et al. “Endometrial adenocarcinoma estrogen receptor content: association of clinicopathologic features with immunohistochemical analysis compared with standard biochemical methods”. American Journal of Obstetrics and Gynecology4 (1987): 924-931.
15. Nyholm HC., et al. “Biochemical and immunohistochemical estrogen and progesterone receptors in adenomatous hyperplasia and endometrial carcinoma: correlations with stage and other clinicopathologic features”. American Journal of Obstetrics and Gynecology5 (1992): 1334-1342.
16. Figueroa-Casas PR., et al. “Reversal by medical treatment of endometrial hyperplasia caused by estrogen replacement therapy”. Menopause6 (2001): 420-423.
17. Reed SD., et al. “Complex hyperplasia with and without atypia: clinical outcomes and implications of progestin therapy”. Obstetrics and Gynecology2-1 (2010): 365-373.
18. Hernandez E. “ACOG Practice Bulletin number 65: management of endometrial cancer”. Obstetrics and Gynecology4 (2006): 952.

Citation

Citation: Jawahar Ramasamy., et al. “A Study on Histopathological Association of Endometrial Hyperplasia with Estrogen Receptor, Progesterone Receptor Status”.Acta Scientific Medical Sciences 6.1 (2022): 226-232.

Copyright

Copyright: © 2022 Jawahar Ramasamy., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.